Here is the design of a clinical trial:

Official Title: Feasibility Study of Tripartite Prehabilitation of Patients With Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndromes During Intensive Chemotherapy Before Allogenic Haematopoietic Stem Cell Transplantation: the COHABILIT Protocol

Included conditions:
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

Study Armgroups:
- {'label': 'Prehabilitation program', 'type': 'EXPERIMENTAL', 'description': 'Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale', 'interventionNames': ['Procedure: Coaching and Habilitation']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'Coaching and Habilitation', 'description': 'nutritional support, adapted physical activity and coaching', 'armGroupLabels': ['Prehabilitation program']}

Primary Outcomes:
- {'measure': 'feasibility to the adapted multidisciplinary program', 'description': 'proportion of patients who will complete more than 50% of the APA/coaching sessions prescribed', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
A power of at least 80% using a one-tailed exact test for binary data with a statistical significance level of 5%.
Sample size
          According to standard design criteria, a sample of 37 allotransplant patients is judged necessary to demonstrate that the proportion of patients with more than 50% of their programmed sessions validated by the coach is greater than the theoretical proportion of 50%, which is considered insufficient. This sample size was determined to ensure a power of at least 80% using a one-tailed exact test for binary data with a statistical significance level of 5%, assuming a minimal true proportion of at least 70%.
          Given an expected proportion of 40% allotransplant patients, it is planned to include 50 patients in order to recruit 37 allotransplant patients.